Suivre
per lonning
per lonning
University of Bergen, Norway
Adresse e-mail validée de helse-bergen.no
Titre
Citée par
Citée par
Année
Molecular portraits of human breast tumours
CM Perou, T Sørlie, MB Eisen, M Van De Rijn, SS Jeffrey, CA Rees, ...
nature 406 (6797), 747, 2000
197562000
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sørlie, CM Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, ...
Proceedings of the National Academy of Sciences 98 (19), 10869-10874, 2001
139642001
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sørlie, R Tibshirani, J Parker, T Hastie, JS Marron, A Nobel, S Deng, ...
Proceedings of the national academy of sciences 100 (14), 8418-8423, 2003
70302003
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
RC Coombes, E Hall, LJ Gibson, R Paridaens, J Jassem, T Delozier, ...
New England Journal of Medicine 350 (11), 1081-1092, 2004
22992004
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors
JR Pollack, JR (Pollack, T Sorlie, T (Sorlie, CM Perou, CM (Perou, ...
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF …, 2002
1481*2002
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
RC Coombes, LS Kilburn, CF Snowdon, R Paridaens, RE Coleman, ...
The Lancet 369 (9561), 559-570, 2007
10792007
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
T Aas, AL Børresen, S Geisler, B Smith-Sørensen, H Johnsen, ...
Nature medicine 2 (7), 811-814, 1996
9591996
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
LR Yates, M Gerstung, S Knappskog, C Desmedt, G Gundem, P Van Loo, ...
Nature medicine 21 (7), 751-759, 2015
8302015
Long-term cultures of bone marrow–derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation
GV Røsland, A Svendsen, A Torsvik, E Sobala, E McCormack, ...
Cancer research 69 (13), 5331-5339, 2009
7962009
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
J Geisler, B Haynes, G Anker, M Dowsett, PE Lønning
Journal of Clinical Oncology 20 (3), 751-757, 2002
7122002
Genomic evolution of breast cancer metastasis and relapse
LR Yates, S Knappskog, D Wedge, JHR Farmery, S Gonzalez, ...
Cancer cell 32 (2), 169-184. e7, 2017
6402017
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer
A Bergamaschi, YH Kim, P Wang, T Sørlie, T Hernandez‐Boussard, ...
Genes, Chromosomes and Cancer 45 (11), 1033-1040, 2006
6082006
Influence of TP53 Gene Alterations and c-erbB-2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer
S Geisler, PE Lønning, T Aas, H Johnsen, Ø Fluge, DF Haugen, ...
Cancer research 61 (6), 2505-2512, 2001
4462001
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial
PE Lønning, E Bajetta, R Murray, M Tubiana-Hulin, PD Eisenberg, ...
Journal of Clinical Oncology 18 (11), 2234-2244, 2000
4142000
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
J Geisler, N King, G Anker, G Ornati, E Di Salle, PE Lønning, M Dowsett
Clinical cancer research: an official journal of the American Association …, 1998
4081998
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
J Geisler, N King, M Dowsett, L Ottestad, S Lundgren, P Walton, ...
British journal of cancer 74 (8), 1286-1291, 1996
4011996
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a …
A Di Leo, S Johnston, KS Lee, E Ciruelos, PE Lønning, W Janni, ...
The Lancet Oncology 19 (1), 87-100, 2018
3852018
Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track–letter
A Torsvik, GV Røsland, A Svendsen, A Molven, H Immervoll, ...
Cancer research 70 (15), 6393-6396, 2010
3572010
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer
PE Lønning, J Geisler, LE Krag, B Erikstein, Y Bremnes, AI Hagen, ...
Journal of Clinical Oncology 23 (22), 5126-5137, 2005
3442005
Mutation of GATA3 in human breast tumors
J Usary, V Llaca, G Karaca, S Presswala, M Karaca, X He, A Langerød, ...
Oncogene 23 (46), 7669-7678, 2004
3112004
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20